title: Cardiovascular toxicities from systemic breast cancer therapy.
abstract: Cardiovascular toxicity is unfortunately a potential short- or long-term sequela of breast cancer therapy. Both conventional chemotherapeutic agents such as anthracyclines and newer targeted agents such as trastuzumab can cause varying degrees of cardiac dysfunction. Type I cardiac toxicity is dose-dependent and irreversible, whereas Type II is not dose-dependent and is generally reversible with cessation of the drug. In this review, we discuss what is currently known about the cardiovascular effects of systemic breast cancer treatments, with a focus on the putative mechanisms of toxicity, the role of biomarkers, and potential methods of preventing and minimizing cardiovascular complications.
authors.affiliation: Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey , New Brunswick, NJ , USA.
authors.forename: Shuang
authors.initials: S
authors.lastname: Guo
authors.affiliation: Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey , New Brunswick, NJ , USA.
authors.forename: Serena
authors.initials: S
authors.lastname: Wong
keywords: anthracycline; breast cancer; cardiotoxicity; chemotherapy; heart failure; trastuzumab